New hope for advanced prostate cancer: drug cocktails enter human trials
NCT ID NCT07230106
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase II study tests two experimental drugs, HS-20093 and SHR2554, combined with standard hormone therapies in 218 men with metastatic prostate cancer. The goal is to see if these combos are safe and can lower PSA levels or slow the cancer's spread. Participants must have adenocarcinoma and be in good overall health.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
HS-20093, SHR2554, abiraterone, enzalutamide, darotamine
What this could lead to
If successful, this could lead to new combination treatments that better control metastatic prostate cancer and delay disease progression.
What could go wrong
This is an early phase II trial with a small number of participants, so results may not apply to all patients. The combinations may cause side effects or fail to improve outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Nanjing Drum Tower Hospital
RECRUITINGNanjing, Jiangsu, 210009, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Tianjin Medical University Cancer Institute and Hospital
RECRUITINGTianjin, Tianjin Municipality, 300060, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact